Sciclone Pharmaceuticals, Inc.

University of Texas System

Sciclone Pharmaceuticals International, Ltd.

The First Affiliated Hospital, Sun Yat-sen University

Cynthia W Tuthill

Alfred R Rudolph

Robert S King

Friedhelm Blobel

Clarence J Peters

Eric C Mossel

Jianfeng Wu

Israel Rios

Xiangdong Guan

Clarence James Peters

The present invention provides compositions and methods for treating cancer or a metastasis thereof in a subject. In some embodiments, the methods involve administering a composition comprising therapeutically effective amount of at least one immune stimulator to the subject. In some embodiments, a combination of at least two immune stimulators is used for the treatment. In some embodiments, the combination includes an alpha thymosin peptide and an additional immune stimulator, and/or optionally one or more additional anti-cancer agents.

Treatment of cancer with alpha thymosin peptide and PD-1 inhibitors

Treatment of cancer with immune stimulators

The present invention provides methods of vaccination as well as pharmaceutical combinations and kits for enhancing vaccine effectiveness, including for immunodeficient or immunecompromised patients, including non-responders and low-responders to vaccination. As disclosed herein, the invention relates to administering a vaccine and a regimen of thymosin alpha peptide so as to provide higher antibody titers, speed the development of such antibody titers, and/or to provide for a longer duration of such antibody titers, thereby providing a greater protective effect. In another aspect, the invention allows for reducing a vaccine dose, such as an influenza vaccine dose, by administration of a thymosin peptide regimen.

Alpha thymosin peptides as vaccine enhancers

An immunomodulatory compound is administered to a patient having, or at risk of a hemorrhagic viral infection.

Treatment or prevention of hemorrhagic viral infections with immunomodulator compounds

An immunomodulatory compound is administered to treat, prevent, inhibit, or reduce melanoma in a subject.

Treatment of melanoma

An immunomodulatory compound is utilized to treat mucosa disease.

Method of treating or preventing tissue deterioration, injury or damage due to disease of mucosa

Damage to cells and/or a subject caused by radiation is treated or prevented by administration of an alpha thymosin peptide.

Methods of protecting against radiation damage using alpha thymosin

A pharmaceutical composition includes a physiologically active conjugate including a Thymosin alpha 1 (TA1) peptide conjugated to a material which increases half-life of the TA1 peptide in serum of a patient when the conjugate is administered to a patient. The material may be a substantially non-antigenic polymer. In a method of the invention, the substantially non-antigenic polymer is conjugated to a TA1 peptide. Compositions according to the invention are administered to patients in need of immune stimulation.

Growing community of inventors

Menlo Park, CA, United States of America

Cynthia W Tuthill